Blindspot Capital

Some markets follow a familiar script: a need emerges, founders respond, capital flows, and eventually, the sector matures. But women’s health doesn’t work like that.In a recent episode of Blindspot Capital, I sat down with Hotflash inc menopause + midlife by Ann Marie McQueen to explore what happens when a market begins not with products or funding but with missing information.When Ann-Marie launched her newsletter in 2020, she wasn’t trying to build a company. She was trying to make sense of her own body. What she found instead was something far bigger: a fragmented, contradictory, and often commercialized information landscape where women were left to navigate perimenopause largely on their own. So she started writing.What began as a weekly research letter has since grown into a global community spanning more than 20,000 women across 40 countries—an ecosystem built not on products, but on trust, nuance, and lived experience.But this conversation is not about content creation. It’s about what has to exist before markets can function at all.We talk about:* Information as infrastructure: why women’s health markets are being built on community-led knowledge systems and what happens when reliable information doesn’t exist* Trust vs. scale: why credibility in women’s health is earned through lived experience and nuance not reach, virality, or clinical authority alone* The danger of certainty: how overly simplified narratives (especially around hormone therapy) can signal bias rather than truth* The education burden on women: why midlife women are forced to become their own researchers, clinicians, and decision-makers in the absence of clear guidance* Fear as a business model: who benefits when women are confused, overwhelmed, or anxious and how that shapes the entire category🎧 Watch the full episode on YouTube📄 Learn more about Hot Flash Inc. and share this episodeJoin 19,000+ readers of The Billion Dollar Blindspot newsletter on Substack.📌 Watch the full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

Some markets follow this script: A need appears. Entrepreneurs respond. Capital flows in. Eventually, the sector matures and innovation accelerates. But some markets don’t follow that script.In a recent episode of Blindspot Capital, I sat down with Lindsay Davis, founder of FemTech Association Asia, to talk about what it actually takes to build women’s health markets in Southeast Asia.When Lindsay moved to Singapore in 2020, she wasn’t planning to work in women’s health. But what she noticed was difficult to ignore: founders, policymakers, and investors were all present, but disconnected. There was no shared infrastructure, no unified ecosystem, and no clear pathway for innovation to scale. So she started building.What began as a simple act of connecting people has evolved into one of the largest specialist networks for women’s health innovation across Asia spanning research, partnerships, founder support, and ecosystem development.But this conversation is not about startup growth. It’s about what has to exist before growth is even possible.We talk about:* Ecosystem building before capital: why markets don’t emerge fully formed and why infrastructure matters long before funding arrives* The education burden on founders: how stigma and low awareness shape how companies are built in Asia* Regional complexity: why Southeast Asia is not a single market, but a matrix of cultures, systems, and behaviors* The visibility gap: how lack of data and precedent keeps women’s health overlooked by investors* Capital flows in Asia: where femtech funding is actually coming from and how that is beginning to shiftWhat emerges from this conversation is a different understanding of women’s health.🎧 Watch the full episode on YouTube📄 Learn more about FemTech Association Asia and share this episode.Join 19,000+ readers of The Billion Dollar Blindspot newsletter on Substack.📌 Watch the full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of Blindspot Capital, Maryann sits down with Cristina Ljungberg and Wendy Anderson, co-founders of The Case for Her, to unpack what happens before venture capital shows up.For 15 years, The Case for Her has deployed catalytic capital across menstruation, sexual wellness, and reproductive health to make markets legible enough for venture to follow.What started with two women putting $5,000 each on a credit card to distribute menstrual cups evolved into one of the most catalytic platforms in global women’s health spanning grants, debt, equity, SAFE notes, research funding, product standards, and systems-level advocacy.This conversation is not about philanthropy versus venture. It’s about how markets form, what it takes to fund the stigmatized. and it’s about why women’s health wasn’t “uninvestable” — it was structurally invisible.This episode is a must-listen for investors looking upstream, founders building in taboo categories, and anyone trying to understand how capital shapes what becomes visible.We talk about:* Catalytic capital: why philanthropy, impact capital, and early-stage risk capital are often required before venture capital can enter a market* The hidden infrastructure problem: how missing standards, regulations, and research can quietly block entire industries from forming* Taboo as a market barrier: why menstruation, sexual health, and reproductive care have historically struggled to attract capital* The pattern recognition gap: why investors often avoid women’s health simply because they have never invested in it beforeThis conversation offers a rare look at the earliest stage of market creation; the phase that happens long before venture capital arrives and long before headlines start calling a sector “the next big opportunity.”If you want to understand where the next wave of women’s health innovation will come from, this episode is a powerful reminder: Markets don’t appear fully formed. They are built.🎧 Watch the full episode on YouTubeLearn more about The Case for Her and catalytic capital in women’s health🔎 Explore the SHIO study on menstrual product choice and market insightsAnd share this episode with founders, operators, and investors building in women’s health — because commercialization blind spots don’t fix themselves.Join 19,000+ readers of The Billion Dollar Blindspot newsletter on Substack.📌 Watch the full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

Most innovation stories are told as clean upward lines. A founder has an idea. Investors come in. The product launches. Growth follows. Eventually there is an acquisition or an IPO, and the story looks inevitable in hindsight.But in women’s health, progress rarely looks like that.More often, there is a long stretch where the science works and yet nothing seems to move. Inside that stretch, entrepreneurs are judged, investors grow impatient, and real progress is often mistaken for failure.In a recent episode of Blindspot Capital, I sat down with Skip Baldino, former CEO of Gynesonics, to talk about what it actually takes to move a women’s health medical technology through a system that was never designed to adopt change quickly.Much of what looks like an “exit” from the outside is, in reality, the end of a very long middle.Gynesonics, which developed a minimally invasive treatment for uterine fibroids as an alternative to hysterectomy, was acquired by Hologic for $350 million last year. Headlines called it a success story. But the journey was not a straight line. It included multiple leadership transitions, product iterations, clinical trials, reimbursement battles, investor fatigue, and even the collapse of Silicon Valley Bank during one of the most fragile moments in the company’s history.At several points, the company could easily have disappeared. Instead, a small group of investors stayed in when others could not or would not. Importantly, the employees stayed in and the company continued building toward a future that was still invisible to the outside world.We talk about:* The hysterectomy default: why 600,000 procedures still happen annually and what it takes to shift the standard* The real work of medtech commercialization: clinical outcomes, economic proof, reimbursement, and payer dynamics* The do-or-die year at Gynesonics and why key opinion leaders matter* The Blackstone signal: what major capital moving into women’s health could mean for founders and exitsThis conversation offers a grounded view of how innovation actually moves through healthcare and why patience, conviction, and sustained capital matter more than headlines suggest.If you care about women’s health innovation, this episode offers a rare look inside the part of the journey most people never see.🎧 Watch the full episode on YouTube📄 Learn more about the Learn more about uterine-sparing fibroid treatment and minimally invasive options.🔎 Explore Channel Medsystems and innovation in heavy menstrual bleedingAnd share this episode with founders, operators, and investors building in women’s health — because commercialization blind spots don’t fix themselves.Join 19,000+ readers of The Billion Dollar Blindspot newsletter on Substack.📌 Watch the full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of Blindspot Capital, Maryann sits down with Professor Angela Maas (cardiologist and pioneer of sex- and gender-specific cardiology) to unpack why women’s heart disease is still misunderstood and what medicine, policy, and innovation must change to close the gap.Angela has built her career at the frontier of women’s cardiovascular science and clinical practice. Her work helped shift the field from “atypical symptoms” and one-size-fits-all assumptions toward a life-course view of women’s heart health spanning pregnancy, midlife, menopause, and the long tail of cancer treatment. This conversation exposes how medical blind spots persist, how cultural resistance slows change, and where cross-disciplinary innovation can unlock better outcomes.This episode is a must-listen for anyone navigating midlife health, clinicians working to close the gender gap in outcomes, and investors seeking the next frontier in precision medicine.We Cover:The moment a female patient confronted Angela and why it became a 35-year wake-up call for her careerWhy women’s ischemic heart disease often isn’t “obstructive” and how spasm and microvascular dysfunction show up differently (especially ages 40–70)The overlooked risk signals hiding in plain sight: migraines, hypertensive pregnancy, miscarriages, early menopause, and severe menopausal symptomsMenopause and “myocardial stiffness” explained in plain language and why prevention must start at the beginning of the transitionThe hidden cardio-oncology gap: how breast cancer treatment can drive heart damage years later, and why early detection mattersWhat sex-specific medical education should include and why policy starts with who holds leadership and decision powerLinksLearn more in Angela’s book, A Woman’s Heart: Why Female Heart Health Really Matters — a definitive guide to understanding women’s cardiovascular risk across the life course.Follow Professor Angela Maas on LinkedInAnd share this episode with a woman navigating midlife health, clinicians and investors because this blind spot doesn’t fix itself.Join 10,000+ readers of The Billion Dollar Blindspot newsletter on Substack.📌 Watch the full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of Blindspot Capital, Maryann Selfe speaks with Professor Carolin Lerchenmüller, cardiologist, clinician-scientist, and Switzerland’s first Chair of Gender Medicine, about why heart disease presents differently in women and how hormones across pregnancy, perimenopause, and menopause fundamentally reshape cardiovascular risk.Drawing on decades of research spanning molecular cardiology and clinical care, Carolin explains why modern cardiology guidelines failed to account for female biology and what gender-informed, hormone-literate cardiology must look like next.We Cover:How pregnancy, perimenopause, and menopause alter cardiovascular symptoms and risk in womenWhy preeclampsia and gestational hypertension are early predictors of lifetime cardiovascular diseaseHow declining estrogen levels affect blood vessels, cholesterol metabolism, and plaque formationWhy cardiovascular disease remains the leading cause of death in women worldwide and why awareness remains dangerously lowWhat a hormone-literate, gender-informed cardiology system would require in research, diagnostics, and care deliveryCarolin’s predictions for the future of gender medicine and why she sees a turning point in science and clinical practiceLinks Learn more about the Women’s Heart Health Program at University Hospital ZurichFollow Professor Lerchenmüller on LinkedInAnd share this episode. With a founder. With a policymaker. With a friend. Because this blind spot doesn’t fix itself.Join 10,000+ readers of the FemmeHealth newsletter on Substack.--------------------------📌 Watch full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of Blindspot Capital, Maryann sits down with Lisa Suennen - longtime healthcare investor, founder of the Venture Valkyrie blog, and Managing Partner of the Go Red for Women Venture Fund to unpack one of the most misunderstood barriers in women’s health investing: the gap between mission and money.Lisa has been on every side of the table: as a founder, VC, nonprofit leader, and fund manager. Her viral blog post, Tough Love for Women’s Health Entrepreneurs, struck a nerve by naming the hard truth many avoid.This episode is a must-listen for founders preparing to pitch, funders looking to cut through the noise, and anyone serious about changing how capital flows into women’s health.We Cover:🟣 Why many femtech startups stall at Series A🟣 The difference between pitching a product vs. pitching your stock🟣 How market size myths derail women's health business cases🟣 Why language matters: from “women’s health” to “health of women”🟣 What Lisa’s seeing across 500+ pitch decks at the AHA Venture Fund🟣 The missing middle: why we need more later-stage capitalLinks:📝 Read Lisa’s blog💼 Learn about the Go Red for Women Venture Fund📣 Follow Lisa on LinkedInAnd share this episode. With a founder. With an investor. With a policymaker. Because this blind spot doesn’t fix itself.Join 10,000+ readers of the FemmeHealth newsletter on Substack.--------------------------📌 Watch full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of Blindspot Capital, Maryann sits down with Anna O’Sullivan, co-founder of censhership.co.uk and FutureFemHealth, to unpack a deeply underrecognized systemic bias: the routine censorship of women’s health content online.Over 95% of women's health brands report experiencing some form of suppression. Posts about menopause, fertility, libido, and endometriosis are being flagged as "sensitive" or "inappropriate" across major platforms even when the content is medically reviewed.This isn’t just a glitch. It’s a structural blind spot that affects funding, awareness, and access.We Cover:🟣 How content moderation is stalling the femtech sector🟣 Case studies from founders facing censorship across Meta, Amazon, and LinkedIn🟣 How Anna’s team filed six complaints under the EU Digital Services Act🟣 The human toll of being silenced while trying to innovate🟣 A new initiative: a vetted directory of service providers for women's health foundersLinks:Download the white paperSign the open letterFollow Anna @FutureFemHealthAnd share this episode. With a founder. With a policymaker. With a friend. Because this blind spot doesn’t fix itself.Join 10,000+ readers of the FemmeHealth newsletter on Substack.--------------------------📌 Watch full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

What if naming something was the first step to making it investable?In this episode of Blindspot Capital, I sit down with Ida Tin, entrepreneur, systems thinker, and the woman who coined the term FemTech. She’s also the co-founder and former CEO of Clue, one of the most widely used women’s health apps in the world, with over 10 million active users in 190+ countries.But this conversation isn’t just about legacy. It’s about language, legitimacy, and the long game of funding women’s health.We cover:🟣 How FemTech started as a bridge to help male investors care🟣 What naming a category unlocked and unintentionally limited🟣 The persistent bias that keeps women’s health boxed in as “niche”🟣 The mindset shift from founder to systems-change leader🟣 Why we believe women’s health is infrastructure🟣 What she’s building next with Femtech Assembly and why she’s doing it differentlyJoin 10,000+ readers of the FemmeHealth newsletter on Substack.--------------------------FEMTECH Assembly--------------------------Why You Should Listen:If you’re a founder, investor, or operator navigating digital health, this is the truth-telling conversation you won’t hear on stage. No fluff. Just data, capital dynamics, and the patterns no one’s naming.📌 Watch full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

Half the headlines in healthcare are hype. But what if we stopped chasing the next shiny thing and started fixing the fundamentals?In this episode of Blindspot Capital, I sit down with Sergei Polevikov, mathematician, investor, and co-host of the podcast Digital Health Inside Out, to talk about what’s broken in digital health from copycat AI startups to gender bias in funding and where we should be paying attention instead.In This Episode We Cover:🟣 Why most digital health startups are chasing performance signals that don’t matter🟣 The VC paradox: how underperforming funds still raise while women founders get ignored🟣 The rise of “AI tourists” in healthcare and why most won’t survive🟣 What investors are missing in autoimmune, menopause, and cardiovascular health🟣 How women-led companies often outperform and still get passed over🟣 What needs to change in how capital flows are structured🟣 Why Sergei and Alex launched Digital Health Inside Out and what he's learning from clinicians, not conferences.Join 10,000+ readers of the FemmeHealth newsletter on Substack.----------------------------------------------------🎙️ Sergei and Alex’s podcast: Digital Health Inside Out📬 Sergei’s Substack: AI Health Uncut----------------------------------------------------Why You Should Listen:If you’re a founder, investor, or operator navigating digital health, this is the truth-telling conversation you won’t hear on stage. No fluff. Just data, capital dynamics, and the patterns no one’s naming.📌 Watch full episode on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

Half the population experiences these conditions. Many are universal, recurring, and clinically significant. Yet in the eyes of too many investors, women’s health therapeutics remain “optional.”In this episode of Blindspot Capital, I sit down with Sabrina Johnson, President & CEO of Daré Bioscience, to unpack the misconceptions holding back investment in women’s health from contraception to menopause to vaginal health and explore how disciplined science can change the game.In This Episode We Cover:🟣 Why women’s health markets are larger and more recurrent than most investors realize🟣 The false perception that women’s health conditions are “lifestyle” or “optional”🟣 The reality of recruiting participants for women’s health trials (and why stigma isn’t a barrier)🟣 What scientific credibility really looks like in biotech and how to protect it🟣 The difference between medicine and marketing and why the distinction matters for investors🟣 Why angel investors have a leadership opportunity in women’s healthJoin 10,000+ readers of the FemmeHealth newsletter on Substack.------------------------------Why You Should Listen If you care about women’s health, biotech, or the intersection of science and capital, this is a clear-eyed look at the market opportunities hiding in plain sight and the leadership it will take to unlock them.About Sabrina Johnson Sabrina Johnson is the President & CEO of Daré Bioscience, a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch.The company’s goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women’s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Learn more Here🎧 Listen now and share with someone who still thinks women’s health is “niche.”📌 Watch on YouTube Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode, healthcare investor and strategist Maryann Umoren Selfe is joined by Matthias Wipf, CEO of Swiss medtech company MOMM Diagnostics, to examine the systemic gaps in how we identify and fund life-saving healthcare infrastructure for women.🟣 Why preeclampsia remains one of the most dangerous, misunderstood pregnancy complications🟣 What point-of-care diagnostics like Pre-Exclude are doing differently🟣 Why diagnostics in women’s health are underfunded and what that reveals about investor psychology🟣 How preeclampsia connects to long-term cardiovascular risk 🟣 What’s holding back innovation in maternal health and how to change it🟣 Why investing in maternal health benefits not just women, but entire health systemsJoin 10,000+ readers of the FemmeHealth newsletter on Substack.------------------About MOMM Diagnostics:Founded in 2018, MOMM Diagnostics is reimagining maternal care with préXclude, a breakthrough test for early detection of preeclampsia. With just a drop of blood and a few minutes, their technology gives clinicians the power to act before pregnancy complications become emergencies. Born out of research collaborations in Switzerland and California, MOMM is part of a new wave of founders who are turning overlooked health problems into high-impact innovation. Learn more here. Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

Blind Spot Capital Podcast TrailerWelcome to Blind Spot Capital, the podcast where health innovation meets investment insight. Every year, investors bet billions on the future of health but most still miss one of the biggest opportunities in the market: women’s health.You tell a woman to “wait and see” while her organ shuts down? That’s not medicine. That’s neglect.We talk to the founders building what should have existed, the investors backing what's next, and the strategists reshaping the capital stack before it’s too late.Subscribe now. New episodes every other Thursday.🎧 Available on Spotify, Apple, Substack, and YouTube. Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

A few weeks ago, Ronald Vos and Nutte van Belzen, the founders of CC Diagnostics were at a major European medical congress when they were approached by a woman who didn’t work in science or medicine. She had bought an expensive delegate ticket, not to participate in the conference, but to seek help.She had advanced cervical cancer. And she came in the hope that someone…anyone, at this gathering of gynaecologists and scientists might listen to her story and offer a lifeline.“We hope all those cases can be prevented,” co-founder Nutte van Belzen reflects.That moment captures exactly why this episode matters.Only 15% of women participate in cervical screenings, despite the fact that cervical cancer is entirely preventable through early detection and vaccination. The problem? Existing methods are invasive, uncomfortable, and all too easy to avoid until it’s too late.In this conversation, the founders of CC Diagnostics share their journey: the personal experience and passion that fuels their mission, the technology they are building to make self-sampling accessible, and their vision for a world where diagnostics are not a privilege, but a right.We also dive into:* The overlooked challenges of building a diagnostics company.* Why many investors hesitate and why that needs to change.* Their roadmap for global access, including a pricing model for low- and middle-income countries (LMICs).This isn’t just a conversation about tech or start-ups.It’s about the human stories that push innovation forward, and the urgent need to act before another woman buys a ticket to beg for care.🎧 Watch the full episode for a powerful and personal look at how we can, and must, do better in women’s health.CC DiagnosticsCC Diagnostics (Netherlands) offers a clinically validated screening test, significantly improving cervical cancer detection rates to 97% (vs current market benchmark of 76%). Our product offers a 6x reduction in time per test for the diagnostic labs, dramatically reducing costs and improving efficiency. Our Methica test technology enables screening from home (with self-sampled material), unlocking a broader €5.5Bn screening market worldwide. We achieved commercial progress, with the first 2 international orders from leading CLIA labs in the US and UK.CC Diagnostics (Netherlands) Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this conversation, Maryann and Astrid Gyllenkrok, CEO and Co-Founder of LEIA Health discuss the challenges of parenthood, particularly focusing on the postpartum experience and the need for better support systems for new parents.Astrid shares her journey in founding LEIA, a Swedish startup on a mission to support the next one billion parents by digitising the parental journey, offering AI-powered support at a time when parents need it the most.They explore the importance of personalized education, the role of employers in supporting parental leave, and the challenges faced by women entrepreneurs in the health sector. The discussion emphasizes the need for advocacy, funding, and systemic change to improve the experiences of parents and promote women's health.Astrid has been named Female Entrepreneur of the Year in Sweden and LEIA has been named One of Europes’ hottest startups by both Sifted, Wired and Business Insider. As a mother of three she's passionate about women's health and changing the narrative around parental health.-----------Mamma app | LEIA | Stockholm Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of FemmeHealth Founders, Maryann speaks with Dr. Lara Zibners, co-founder of Calla Lily Clinical Care, about the inadequacies in current drug delivery methods for women's health. Lara shares her personal journey from being a physician to an entrepreneur, driven by her own experiences with infertility and the challenges of existing treatments. With a broad background in clinical medicine and medical education in both the US and UK, Lara brings a unique understanding to Calla Lily of the scientific, systematic and business challenges facing women’s healthcare.-----------Current methods of vaginal drug delivery are profoundly inadequate for millions of women around the world. Calla Lily has developed a new leak-free vaginal drug delivery platform. It's simple to use (essential when patients have to administer medications themselves) and also helps to alleviate dosage anxiety and other stresses.Innovators in Vaginal Drug Delivery | Calla Lily Clinical Care Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

In this episode of Notes to Selfe, we dive into the fascinating world of women's health innovation with Sebastian Alexander, founder and CEO of VivoSensMedical. We explore the journey of OvulaRing, a groundbreaking technology transforming the way we understand and address female fertility and gynaecological diagnostics.From the legacy of Sebastian's father-in-law, a pioneer in IVF and reproductive medicine, to the challenges of building a company in an underfunded and often overlooked sector, this episode is a deep dive into the realities of advancing women's health.Together, we discuss:* The unmet needs in women's reproductive health.* How core body temperature is revolutionising fertility diagnostics.* The gender data gap in healthcare and why it matters.* The importance of patient capital in driving women's health innovation.* How value-aligned investors can play a pivotal role in transforming the future of women's health.If you are an investor, founder, or simply someone passionate about advancing healthcare for women, this episode will inspire and inform you.----------VivoSensMedical GmbH is a young, medical company from Leipzig that combines medical-scientific experience, technical know-how, marketing and sales expertise, and management practice. The company's vision is to transfer a wealth of experience of over 40 years of scientific work in clinical and user-friendly products to benefit both patients and doctors. VivoSensMedical strives to set new standards in diagnosis and treatment in the fields of gynaecology, reproductive and sexual medicine, and immunology and autoimmune diseases.vivosensmedical.comOvulaRing cycle tracker - determines your ovulation precisely Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

Hormones rule our lives—from puberty to menopause, they influence everything from our mood to our health. But why do some women experience severe side effects while others don’t?In this episode of the FemmeHealth Founder Series, I sit down with Dr. Paulina Cecula, co-founder of Dama Health, to:📌 explore the groundbreaking science behind personalized hormone therapy.📌 discuss the complex interplay of genetics, metabolism, and microbiome, and why trial-and-error contraception needs to become a thing of the past.If you’re curious about the future of precision medicine in women’s health or simply want to understand your body better, this is an episode you can’t miss.-------------------------Dama Health with consortium partners Nura Health and Lasa Health, have recently been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health, to address critical unmet challenges in women’s health. Dama Health and its consortium partners will receive $3 million in funding over two years for early stage research efforts.***Disclaimer***All opinions are my own and personal. This is not investment advice. I do not provide any buying or selling recommendations, nor do I offer any investment advice. You are advised to conduct your own research and due diligence when making financial and investment decisions. Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe